About Careers MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

FDA Gives Preliminary Nod To Cipla And Sun Drugs

by Medindia Content Team on May 23, 2006 at 6:16 PM
Font : A-A+

FDA Gives Preliminary Nod To Cipla And Sun Drugs

A U.S. Food and Drug Administration statement has said that drug maker Cipla Ltd. has been given tentative approval for its generic AIDS drug nevirapine that is to be marketed in a tablet form.

Sun Pharma Ltd has also received similar approval for ondansetron in the injection form.

Advertisement

Ondansetron is used to prevent of nausea and vomiting following chemotherapy or radiation therapy for cancer. The drug is the generic equivalent of GlaxoSmithKline's Zofran injection.

Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
World Disability Day 2022 - The Role of Innovative Transformation
Diet and Oral Health: The Sugary Connection May Become Sour
World AIDS Day 2022 - Equalize!
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drug Toxicity Signature Drug Toxicity 

Most Popular on Medindia

Blood Donation - Recipients Daily Calorie Requirements Nutam (400mg) (Piracetam) Noscaphene (Noscapine) Find a Hospital Pregnancy Confirmation Calculator How to Reduce School Bag Weight - Simple Tips Calculate Ideal Weight for Infants Blood - Sugar Chart Hearing Loss Calculator
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
×

FDA Gives Preliminary Nod To Cipla And Sun Drugs Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests